



RxFiles Drug Comparison Charts

13th Edition (Aug 2021)

CHART PEARLS

BY THE NUMBERS

Total pages: **246** New charts: **22**
Changes: **thousands**. Charts updated **daily**, then also sent to web/app.

NEW and REVAMPED CHARTS

Heart Failure	pg. 23-26
Head Lice & Scabies	pg. 33
Warts	pg. 34
Perspectives on Glycemic Targets: Individualizing – benefit vs harms	pg. 40
Modifiable Risk Factors for CV & Renal Protection	pg. 41
Perspectives on Diabetes & the Kidneys	pg. 42
Anti-hyperglycemic, GLP1 & SGLT2 Colour Comparisons	pg. 43-44
Adult Vaccines	pg. 79-80
HIV (Human Immunodeficiency Virus) & PrEP:	pg. 107-110
Principles of Chronic Pain Management	pg. 123-124
Methadone & Buprenorphine/Naloxone Colour Comparison	pg. 135
Acute on Chronic Pain	pg. 142
Birth Control Colour Comparison & Prescribing Information	pg. 171-172
Psychotic disorders: Overview and Approach to Therapy	pg. 189-192
Cystic Fibrosis	pg. 200

SCANNING through the CHARTS

Some Highlights Include:	Go To...
Expansion of Diabetes Outcomes Colour Chart, with a 2 nd page focusing specifically on the advantages and disadvantages of GLP1a's and SGLT2's	pg. 43-44
New algorithm to approach insulin initiation in people with T2DM including tips on troubleshooting and switching insulins	pg. 49-52
Significant revisions to antivirals and influenza vaccines with a new section responding to vaccine myths.	pg. 111
Addition of SUBOXONE and methadone colour comparison chart outlining efficacy, adverse events, convenience, and more.	pg. 135
MS has been expanded to two pages now including an overview highlighting clinical pearls and an approach to therapy and symptom management.	pg. 157-158
Expansion of Parkinson's Disease, now including a mini colour comparison of Parkinson's agents, tips on optimizing levodopa therapy, and managing the side effects from Parkinson's medications.	pg. 162-164
Revision and expansion of emergency contraception and medical abortion.	pg. 169-170
New psychotic disorders chart that includes information on treatment resistant schizophrenia, clozapine initiation/monitoring and how to initiate and monitor long-acting injections.	pg. 189-192

SOME OF THE GUIDELINES REVIEWED

- Cardiovascular:** Cardiovascular Risk Reduction in T2DM^{ACC²⁰}, Management of A.fib^{CCS²⁰}, A.fib Diagnosis and Monitoring^{ESC²⁰}, A.fib or VTE undergoing PCI/ASCVD^{ACC²⁰}, Manage VTE: Prevent & Tx pts with Cancer^{ASH²¹}, Heart Failure Guideline Update^{CCS²¹}, Management of Blood Pressure in CKD^{KDIGO²¹}, Lipid Guidelines^{CCS²¹}, Menopause Tx and CVD Risk^{AHA²⁰}
- Endocrine & Metabolic:** American Diabetes Guidelines^{ADA²¹}, Diabetes Canada Update^{DC²⁰}, Obesity Canada^{OC²⁰}
- Neuro/Psych:** Schizophrenia Guideline^{APA²⁰}
- Respiratory:** Management of Very Mild Asthma^{CTS²¹}, American Asthma Guide: Adult/Adolescent^{NAEPP²⁰}
- ID:** HIV^{IAS-USA²⁰}, CAP^{IDS/ATS¹⁹}, C. diff Guidelines^{IDS/SHA²¹}, STI Guidelines^{CDC²¹}
- Others:** Rheumatoid Arthritis^{ACR²¹}, Irritable Bowel Syndrome^{ACG²⁰}, Upper Gastrointestinal & Ulcer Guideline^{ACG²¹}, Parkinson Disease^{CAN¹⁹}, Osteoporosis^{AACE/ACE²⁰, SIGN²⁰}, Insomnia^{AASM²¹}

PRICE CHANGES

Price Decrease:

- MIRENA** was \$400, now \$375
- SATIVEX** was \$700 for the 3-vial pack, now \$673
- INVEGA** was \$225-285, now \$180-240

Price Increase:

- MALARONE** was \$69 for a 4 week course, now \$143
- AVENTYL** was \$28-79, now it is \$49-105
- DOVATO** was \$940, now \$970

NEW DRUG (BRAND NAME) ADDITIONS

AJOVY, ATECTURA, ENERZAIR, CABENUVA, LUNESTA, NEXPLANON, OSNUVO, SPRAVATO, SUVEXX, TIBELLA, AERMONY RESPICLICK, CORZYNA, COMBOGESIC, DAYVIGO, ENTYVIO, KESIMPTA, ZEPOSIA, SUBOXONE FILM, TRURAPI, VOCABRIA, RYBELSUS, ADMELOG, XOFLUZA, XENLETA... LOTS!

FORMULARY CHANGES

- New generics:** **CIPRODEX, CYTOMEL, DOVOBET OINT**, flecainide, **FLOVENT, BIOSIMILARS (HUMIRA, ADMELOG, TRURAPI), INFILXIMAB, JADENU, KAYEXALATE**, methotrexate inj, **MYFORIC, ONGLYZA, RAPAFLO, RENVELA, REVATIO, RITUXIMAB, TRI-CIRA, ULORIC, VENOFRER, VISANNE**, acarbose, itraconazole soln, labetalol, **LEUCOVORIN, MESTINON**, methimazole, methotrexate subcut, oseltamivir, **ROCALTRON, YASMIN**.
- New SK Formulary:** **DOACS FOR A.FIB & DVT/PE DURING COVID-19, ADMELOG, AERMONY RESPICLICK, GLUCONORM, TRINTELLIX, MYA, ZAMINE, SUBOXONE, SPIRIVA**.
- New EDS:** **ADLYXINE, AVSOLA, DUPIXENT, FASERNRA PEN, OMNIPOD CARTRIDGE, OLUMITANT, ONPATTRO, OPSUMIT, ORKAMBI, RITUXIMAB (VIA RIXIMYO, RUXIENCE, AND TRUXIMA), REVESTIVE, SOLIQUA, TAKHYRO AND VISANNE, COAGUCHEK, CRESEMBA**, linezolid, **MAVENCLAD, OZEMPIC, DOVATO, JULUCA, XARELTO 2.5mg**.
- New NIHB:** **ADMELOG, ANDROGEL 2.5g, CAMPRAL**, cyclosporine, **DEX-4 LIQUID/GEL, EMEND, IRON POLYSACCHARIDE COMPLEX (TRIFEREXX, POLYRIDE FE, FERAMAX), MEZERA 1gm FOAM, MINOCYCLINE, MONUROL, MYCOPHENOLATE, NABILONE, SHINGRIX (FOR AGE 65-70YRS ONLY), sirolimus, tacrolimus, TRINTELLIX, VIREAD, ZYVOXAM, FORXIGA, JENTADUETO, KOMBOLYZE, XIGDUO, SOLIQUA, DOVATO**.
(▼ used when has SPDP restrictions)
- New NIHB prior approval:** **HUMIRA 20mg SYRINGE, PREVMIS, RIXIMYO, COAGUCHEK, CRESEMBA**, linezolid, **MAVENCLAD, XARELTO 2.5mg, ANDROGEL 1.25g pump, 5g**.

OUTCOME EVIDENCE FROM MAJOR TRIALS

Major outcome trials & drug dosages used are often noted on charts when pertinent. Relatively recent:

- DAPA-CKD** (dapagliflozin vs placebo),
- VICTORIA** (vericiguat global study in subjects with heart failure with reduced ejection fraction), **EMPEROR-Reduced** (empagliflozin vs placebo in HFrEF),
- DECLARE-TIMI 58** (dapagliflozin vs placebo in type II diabetes), **CREDESCENCE** (canagliflozin vs placebo in type II diabetes with CKD), **DAPA-HF** (dapagliflozin vs placebo in heart failure), **SELECT-CHOICE** (upadacitinib vs abatacept),
- ETHOS** (triple inhaled therapy at two glucocorticoid doses)



RxFiles Academic Detailing

University of Saskatchewan
College of Pharmacy and Nutrition
104 Clinic Place, Saskatoon, SK Canada S7N2Z4
TEL: (306)966-5972 FAX: (306)966-5387
Email: via our website www.RxFiles.ca



UNIVERSITY OF SASKATCHEWAN
College of Pharmacy and Nutrition
PHARMACY-NUTRITION.USASK.CA

RECENT ADVERSE REACTION ADVISORY

Health Canada [Advisories, Warnings and Recalls - Health Canada](#) & FDA

- **Fibristal** Sept/20: discontinued due to liver toxicity
- **CHAMPIX** June/21: Five lots were associated with nitrosamine impurity, N-nitrosovarenicline, above the acceptable intake limit established by Health Canada. Similar impurity as ranitidine.
- **Minocycline** July/21: blue-grey Induced hyperpigmentation
- **Mirtazapine** June/21: the use of mirtazapine in patients with major depressive disorder may increase their risk of mirtazapine-induced hypothyroxinemia
- **Diltiazem** May/21: Gingival hyperplasia associated with diltiazem use
- **Montelukast** March/20: FDA black box warning for psych risk

COLORS SPEAK A 1000 WORDS...

Colours used within the Charts

Green shading usually indicates HERBAL/LIFESTYLE related
Blue shading usually indicates PEDIATRIC related
Dark Blue shading usually indicates ADOLESCENT related
Tan shading usually indicates GERIATRIC/OLD adults related
Purple script usually indicates TRADE NAMES
Yellow highlights CLINICAL DIFFERENCES, PRACTICE GAPS & COMMON ?'s
Blue script usually indicates MAJOR TRIALS
Pink script usually indicates PREGNANCY & LACTATION related
Red shading usually indicates official FDA black box or HC warning
Gray script usually indicates DISCONTINUED drug
Purple shading usually indicates OVERVIEW/GUIDELINE approach



See our Geri-RxFiles 3rd ed. for useful tools, tips and strategies when caring for older adults!

<https://www.rxfiles.ca/rxfiles/uploads/documents/1A-CHT-Book-ORDERFORM-Geri-RxFiles.pdf>

RxFiles Online www.RxFiles.ca

- ✓ Subscribe to RxFiles email updates, Facebook & Instagram pages
- For those with subscription or a Saskatchewan SHIRP account...
- ✓ **Drug comparison charts** with weekly website updates
- ✓ **RxFiles+ app** with quarterly updates; download on your iPad, iPhone or Android device
- ✓ Other features: links, program information, references, search function

Link to order form: <http://www.rxfiles.ca/rxfiles/uploads/documents/1A-CHT-Book-ORDERFORM.pdf>

Our Editors: Brent Jensen, Loren Regier, Lynette Kosar, Julia Bareham, Alex Crawley, Marlys LeBras, Taisa Trischuk, Margaret Jin

SYMBOLS

	Canada (We are Canadian)		
	Non-formulary in Saskatchewan		
	Exception Drug Status (EDS) in Saskatchewan (SK) (1-800-667-2549)		
	Not covered by NIHB (Non-Insured Health Benefits) https://www.canada.ca/en/indigenous-services-canada/services/non-insured-health-benefits-first-nations-inuit/benefits-services-under-non-insured-health-benefits-program/drugs-pharmacy-benefits/drug-benefit-list.html		
	Prior approval required by NIHB. Coverage for eligible First Nations & Inuit (1-800-580-0950)		
	Covered by NIHB. Identified ONLY for those drugs that have SK Formulary restrictions such as EDS or non-formulary status .		
	Retail <i>Cost to Consumer</i> price based on acquisition cost, markup & dispensing fee in Saskatchewan. Lowest generic price used when where available.		
	Full medication coverage by the Saskatchewan Cancer Centre		
	Warfarin interactions on the herbal chart		
	Tablet is scored. Appears as superscript, e.g. 25 ⁵ mg tablet.		
	Tastes good		
	Concern if drug or herbal is given Pre-Op		
	Avoid if patient has soybean & peanut allergy		
	Male		Female
	Dose ↓ may be required for liver dysfunction		
	Dose ↓ required for renal dysfunction if 1) drug ≥ 75% renal excretion 2) toxic if accumulates 3) an active metabolite requiring dose adjustment. [CrCl <60mL/min indicates impaired renal function]		

COMMONLY USED ABBREVIATIONS

AE	Adverse event
BID	Twice daily
BP	Blood pressure
bz	Benzodiazepine
CI	Contraindication
CV	Cardiovascular
D	Drug interaction
dx	Diagnosis/disease
HSR	Hypersensitivity reaction
LFT	Liver function tests
M	Monitoring
OTC	Over the counter
HTN	Hypertension
QID	Four times daily
eGFR	Estimated glomerular filtration rate
g	Generic available
GI	Gastrointestinal
HA	Headache
HF	Heart failure
HR	Heart rate
HS	Bedtime
SCr	Serum creatinine
SJS	Stevens Johnson Syndrome
sx	Syndrome/symptom
sz	Seizure
TID	Three times daily
tx	Treatment/Therapy
BMD	Bone mineral density
MI	Myocardial infarction
NNT	Number needed to treat
NNH	Number needed to harm

DRUGS IN PREGNANCY & LACTATION RISK CATEGORIES

PREGNANCY [P]	LACTATION [L]
Safe	Safe
<ul style="list-style-type: none"> • Compatible in pregnancy 	<ul style="list-style-type: none"> • Compatible in breastfeeding
Likely Safe	Likely Safe
<ul style="list-style-type: none"> • No (limited) human data – probably compatible • Compatible: maternal benefit >> embryo-fetal risk • Human data suggest low risk 	<ul style="list-style-type: none"> • No (limited) human data – probably compatible
Caution	Caution
<ul style="list-style-type: none"> • Human, and or animal, data suggest risk • Potential risk in specific trimester(s), as indicated by 'x' 	<ul style="list-style-type: none"> • Hold/delay breastfeeding • No (limited) human data – potential toxicity
Contraindicated	Contraindicated
<ul style="list-style-type: none"> • Contraindicated in pregnancy • Contraindicated in specific trimester(s), as indicated by 'x' 	<ul style="list-style-type: none"> • Contraindicated in breastfeeding
Unknown for Pregnancy and/or Lactation	<p>What you'll see in the charts: P = pregnancy L = lactation risk category Colours correspond to risk categories outlined in this table. Example, warfarin: P = contraindicated 1st trimester L = compatible during lactation</p>
<ul style="list-style-type: none"> • No (limited) human data – no relevant animal data 	
<p>Reference: Drugs in Pregnancy and Lactation. 11th ed. Briggs GG, Freeman RK, Towers CV, Forinash AB, editors. Williams & Wilkins; Philadelphia, PA: 2017.</p>	